Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria.
Hegenbart U, Niederwieser D, Forman S, Holler E, Leiblein S, Johnston L, Pönisch W, Epner E, Witherspoon R, Blume K, Storb R. Hegenbart U, et al. Among authors: leiblein s. Biol Blood Marrow Transplant. 2003 Nov;9(11):689-97. doi: 10.1016/s1083-8791(03)00264-7. Biol Blood Marrow Transplant. 2003. PMID: 14652852 Free article.
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D. Lange T, et al. Among authors: leiblein s. Leukemia. 2004 Sep;18(9):1468-75. doi: 10.1038/sj.leu.2403425. Leukemia. 2004. PMID: 15241437
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K, Iacobelli S, Leiblein S, Eisfeld AK, Pfrepper C, Heyn S, Vucinic V, Franke GN, Krahl R, Fricke S, Becker C, Pönisch W, Behre G, Niederwieser D, Lange T. Hebenstreit K, et al. Among authors: leiblein s. Leuk Lymphoma. 2014 Jun;55(6):1274-80. doi: 10.3109/10428194.2013.836598. Epub 2013 Oct 3. Leuk Lymphoma. 2014. PMID: 23964650
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.
Hell S, Jentzsch M, Franke GN, Jäkel N, Schulze S, Edelmann J, Nenoff K, Grieb N, Jeremic V, Cross M, Leiblein S, Bach E, Pönisch W, Al-Ali HK, Schwind S, Platzbecker U, Lange T, Niederwieser D, Vucinic V. Hell S, et al. Among authors: leiblein s. Bone Marrow Transplant. 2022 May;57(5):824-826. doi: 10.1038/s41409-022-01609-6. Epub 2022 Feb 18. Bone Marrow Transplant. 2022. PMID: 35181744 Free PMC article. Clinical Trial. No abstract available.
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Deininger M, Pönisch W, Krahl R, Leiblein S, Edel E, Lange T, Fiedler F, Freund M, Franke A, Pasold R, von Grünhagen U, Herold M, Dölken G, Hoffmann FA, Uhle R, Schultze W, Steglich J, Schwarzer A, Richter P, Winkelmann C, Kettner E, Dachselt K, Subert R, Schwalbe E, Doepper J, Helbig W, Niederwieser D; East German Study Group Haematology/Oncology (OSHO). Deininger M, et al. Among authors: leiblein s. Bone Marrow Transplant. 2001 Jun;27(11):1125-32. doi: 10.1038/sj.bmt.1703057. Bone Marrow Transplant. 2001. PMID: 11551022 Clinical Trial.
Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D. Lange T, et al. Among authors: leiblein s. Leukemia. 2011 Mar;25(3):498-505. doi: 10.1038/leu.2010.283. Epub 2010 Dec 7. Leukemia. 2011. PMID: 21135860
Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39).
Vucinic V, Jentzsch M, Leiblein S, Bach E, Remane Y, Schulze-Forster K, Cross M, Pönisch W, Schwind S, Franke GN, Platzbecker U, Niederwieser D. Vucinic V, et al. Among authors: leiblein s. Transfusion. 2022 Jan;62(1):157-164. doi: 10.1111/trf.16761. Epub 2021 Dec 10. Transfusion. 2022. PMID: 34893987 Clinical Trial.
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Pönisch W, Franke GN, Vucinic V, Lange T, Behre G, Mrózek K, Bloomfield CD, Niederwieser D, Schwind S. Jentzsch M, et al. Among authors: leiblein s. Am J Hematol. 2017 Apr;92(4):388-396. doi: 10.1002/ajh.24663. Epub 2017 Feb 21. Am J Hematol. 2017. PMID: 28133783 Free article.
37 results